Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc. (NBIX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: Neurocrine is a neuroscience-focused biopharmaceutical company developing treatments for neuropsychiatric, neurological, and neuroendocrine disorders. Key commercial products include INGREZZA (valbenazine) for tardive dyskinesia and Huntington's disease chorea, and CRENESSITY (crinecerfont) for classic congenital adrenal hyperplasia (CAH), launched in December 2024.
Key Financial Metrics
| Financial Metric (in millions) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Total Revenues | $687.5 | $590.2 | $1,260.1 | $1,105.5 |
| Net Product Sales | $682.0 | $583.8 | $1,245.7 | $1,092.8 |
| Operating Income | $145.6 | $145.4 | $169.2 | $244.7 |
| Net Income | $107.5 | $65.0 | $115.4 | $108.4 |
| Diluted EPS | $1.06 | $0.63 | $1.13 | $1.04 |
| Operating Cash Flow (YTD) | $166.8 | $194.9 | $166.8 | $194.9 |
| Cash & Equivalents (Balance Sheet) | $264.0 | $233.0 | $264.0 | $233.0 |
| Total Assets | $3,889.8 | $3,718.7 | $3,889.8 | $3,718.7 |
Liquidity & Capital: As of June 30, 2025, the company held $1.85 billion in total cash, cash equivalents, and marketable securities. Working capital was $1.20 billion. The company has no long-term debt outstanding following the settlement of convertible senior notes in May 2024.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 16.5% in Q2 2025 and 14.0% YTD 2025 compared to the prior year. This was driven by a 7.7% increase in INGREZZA sales and the contribution of $53.2 million in CRENESSITY sales in Q2 2025 (launched Dec 2024).
- Operating Expenses: Research and Development (R&D) expenses increased significantly to $244.3 million in Q2 2025 (up 27.8% YoY) and $507.5 million YTD (up 44.8% YoY). Increases were due to higher investment in Phase 3 programs (osavampator, NBI-1117568), increased headcount, and milestone payments totaling $60.5 million YTD.
- SG&A Expenses: Selling, General, and Administrative expenses rose to $286.3 million in Q2 2025 (up 18.3% YoY), reflecting commercial expansion for CRENESSITY and INGREZZA, and the absence of a $14.0 million impairment charge recorded in Q2 2024 related to legacy facilities.
- Other Income/Expense: Net income benefited from the absence of $138.4 million in charges associated with convertible senior notes that occurred in the first six months of 2024. However, the company recorded an unrealized loss of $37.3 million on equity investments YTD 2025.
- Share Repurchases: The company repurchased $167.7 million of common stock YTD 2025 under a new $500 million program authorized in February 2025, in addition to completing a $300 million accelerated repurchase program in February 2025.
Guidance, Outlook, and Risks
Management Commentary & Pipeline:
- Commercial Strategy: Focus remains on maximizing INGREZZA and CRENESSITY. INGREZZA qualified for the small biotech exception under the Medicare Drug Price Negotiation Program, exempting it from selection until 2027.
- Pipeline Progress: Initiated Phase 3 studies for NBI-1117568 (schizophrenia) and osavampator (major depressive disorder). Initiated Phase 1 studies for NBI-921355 (epilepsy) and NBI-1140675 (VMAT2 inhibitor).
- Disappointments: Announced that the Phase 3 study of valbenazine for adjunctive treatment of schizophrenia did not meet its primary endpoint.
Risks & Contingencies:
- Legal Proceedings: Filed suit against Zydus Pharmaceuticals regarding a generic application for INGREZZA SPRINKLE. Also engaged in patent disputes with Spruce Biosciences.
- Regulatory & Tax: The "One Big Beautiful Bill Act" (OBBBA) signed July 4, 2025, made permanent key tax elements (100% bonus depreciation, R&D expensing). The impact is being evaluated and will be reflected in the Q3 2025 filing.
- Customer Concentration: Four customers accounted for over 90% of total gross product sales.
- Collaboration Milestones: Potential future milestone payments under collaboration agreements could total up to $14.0 billion.
Investor Verification Checklist
- CRENESSITY Adoption: Verify the trajectory of CRENESSITY sales following its December 2024 launch to ensure it meets commercialization expectations.
- R&D Efficiency: Monitor the high burn rate in R&D ($507.5M YTD) relative to clinical milestones, particularly given the recent Phase 3 failure for valbenazine in schizophrenia.
- Generic Competition: Track the status of the litigation against Zydus regarding the generic INGREZZA SPRINKLE application.
- Share Repurchase Impact: Assess the remaining $332.3 million authorization under the 2025 repurchase program and its effect on future cash flow and EPS.
- Tax Legislation Impact: Review the Q3 2025 filing for the quantified impact of the OBBBA on deferred tax assets and effective tax rates.